Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Marinos C. Dalakas MD, FAAN Advisory Board

Mark Hallett MD Editor-in-Chief

See All Experts

featured

Published in Neurology and

Journal Scan / Research · March 16, 2021

Autologous HSTC in Patients With "Aggressive" MS

Multiple Sclerosis (Houndmills, Basingstoke, England)

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Additional Info

Long-Term Clinical Outcomes of HSCT in MS

Disclosure statements are available on the authors' profiles:

Harry Atkins MD

Kyle Binder MD

Mark Freedman HBSc, MSc, MD, CSPQ, FANA, FAAN, FRCPC

Multiple Sclerosis (Houndmills, Basingstoke, England)

Autologous Haematopoietic Stem Cell Transplantation as a First-Line Disease-Modifying Therapy in Patients With 'Aggressive' Multiple Sclerosis

Mult. Scler. 2021 Feb 10;[EPub Ahead of Print], J Das, JA Snowden, J Burman, MS Freedman, H Atkins, M Bowman, RK Burt, R Saccardi, C Innocenti, S Mistry, PJ Laud, H Jessop, B Sharrack

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Notice to Our Valued Users

Multiple Sclerosis

Autologous HSTC in Patients With "Aggressive" MS

Additional Info

Autologous Haematopoietic Stem Cell Transplantation as a First-Line Disease-Modifying Therapy in Patients With 'Aggressive' Multiple Sclerosis

Further Reading

Final Note From the Neurology Editors

Association of Health and Lifestyle Factors With Dementia Risk in Former Professional Soccer Players

Association of the Cervical Canal Area With Disability and Progression in People With MS

Directional Subthalamic Deep Brain Stimulation Better Improves Gait and Balance Disorders in Patients With Parkinson's Disease

Induction Cyclophosphamide With Maintenance Immunosuppression for High-Risk Myasthenia Gravis

Non-Invasive Continuous Oral Delivery of Solid Levodopa–Carbidopa for the Management of Parkinson's Disease

Low-Frequency Deep Brain Stimulation During Non-REM Sleep Modifies Memory Retention in Patients With Parkinson's Disease

Toward Personalized Dosing of B-Cell–Depleting Therapy

Safety and Efficacy of Intravenous Recombinant Human Prourokinase for Acute Ischaemic Stroke Within 4.5 Hours After Stroke Onset

Hypogammaglobulinemia and Severe Infections in Patients With MS on Anti-CD20 Agents

Risk of Hypertension in Patients With MS Treated With Teriflunomide vs Dimethyl Fumarate

Recently Updated